查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1840839

基於NGS的RNA定序市場（按應用、產品、最終用戶和技術）－全球預測2025-2032

NGS-Based RNA-Sequencing Market by Application, Product, End User, Technology - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基於 NGS 的 RNA定序市場將成長至 102 億美元，複合年成長率為 18.21%。

主要市場統計數據
基準年2024年 26.7億美元
預計2025年 31.7億美元
預測年份：2032年 102億美元
複合年成長率（%） 18.21%

全面介紹基於NGS的RNA定序創新及其對臨床流程和轉化研究生物資訊整合的影響

基於次世代定序儀(NGS) 的 RNA 定序已從學術研究發展成為支持發現、診斷和治療開發的基礎平台。這項技術能夠以高靈敏度和解析度定量轉錄組，現已支持從生物標記鑑定到研究細胞異質性的多種應用。隨著實驗室採用更複雜的工作流程和計算流程，RNA定序在從早期研究到臨床應用的決策中的作用日益凸顯。

此外，文庫製備、讀長最佳化和多模態整合的創新正在拓展RNA定序在複雜生物環境中的效用。這些技術進步伴隨著實驗室實踐的轉變、對可重複分析的期望不斷提高以及對監管合規的新要求。因此，學術界、診斷學界和產業界的領導者不僅必須了解技術本身，還必須了解樣本處理、資料管治和跨學科合作等營運方面的考量。

本介紹為需要將其科學能力與策略目標結合的相關人員提供了一個討論框架，強調了為什麼 RNA 定序現在已成為轉化流程中的核心資產，並概述了以下章節中的觀點。

重新定義跨學科 RNA 定序研究、臨床轉化和生物資訊學工作流程的變革性轉變

RNA定序模式正在再形成，這不僅源自於原始通量的提升，也源自於多種因素的匯聚。首先，從批量轉錄組學到單細胞和空間轉錄組學的轉變，透過揭示細胞異質性和組織結構，從根本上改變了生物學解讀。這種轉變需要新的樣品製備方案、複雜的品管以及能夠解析稀疏數據的分析方法。因此，研究團隊現在在設計實驗時會考慮細胞解析度，這會影響從試劑選擇到下游計算資源的各個方面。

其次，長讀長定序技術作為補充方法應運而生，能夠偵測短讀長技術常常遺漏的全長異構體和複雜的轉錄本結構。這種能力加速了我們對可變剪接、融合轉錄物和轉錄本異構體調控的理解，並有助於標靶檢驗和生物標記最佳化。由於不同的錯誤概況和資料格式，採用長讀長方法也需要重新評估文庫建置工作流程和資料儲存方法。

第三，與多體學和雲端生物資訊學平台的整合正在推動跨實驗室的協作和可重複分析。模組化和可互通的工作流程使團隊能夠將轉錄組數據與蛋白質組學和表觀基因相結合，從而產生更穩健的生物學假設。這些轉變不僅僅是技術上的；它們正在改變組織機構確定投資優先順序、建立合作機制以及將研究發現轉化為臨床應用的方式。

2025年美國提案關稅對RNA定序工作流程營運成本、供應鏈和策略採購的累積影響

影響關稅的政策變化會波及生命科學供應鏈，影響成本、供應商關係和籌資策略。在試劑、設備和專用耗材跨境運輸的情況下，關稅上漲會增加貨物的到岸成本，並促使企業重新評估籌資策略。對於許多實驗室而言，這會導致採購週期延長，更加重視庫存管理，採購團隊也會優先考慮更長的前置作業時間和尋找替代供應商，以緩解供應中斷的影響。

此外，由於研究機構和供應商力求降低跨境關稅和貨幣波動的影響，關稅可能會加速在地化和近岸外包的進程。供應商可以透過建立區域製造中心或最佳化產品系列來應對，以減少受關稅影響的零件數量。同時，服務供應商和委外研發機構也可以透過提供端到端的交鑰匙解決方案來簡化研究機構和臨床實驗室的採購流程，從而為客戶吸收部分供應鏈風險。

因此，研究團隊在選擇儀器和耗材時，必須審查供應商合約條款，考慮多方採購，並考慮整體擁有成本。此外，策略性採購決策將越來越強調在試劑和平台之間靈活切換，同時又不影響供應的連續性、區域支援和數據可比較性。最終，關稅相關的壓力正促使企業採用更具彈性的供應鏈策略，並更加重視平衡成本、可靠性和績效的夥伴關係模式。

將應用產品最終用戶和技術與差異化工作流程和價值創造路徑連結起來的關鍵細分洞察

透過應用視角分析採用情況，可以揭示影響需求和投資的不同用例。生物標記發現著重於早期識別和檢驗，需要高通量可重複性和嚴格的檢驗流程，以支援下游臨床應用。藥物動力學研究強調定量準確性，標靶辨識需要廣泛的轉錄組覆蓋，毒性研究則優先考慮對稀有或低豐度轉錄物的敏感性。基因表現表現譜分析涵蓋適用於群體層級訊號的批量方法，以及單細胞和空間分析，以揭示細胞和微環境的細微差別。個人化醫療需要整合伴隨診斷和治療監測，以提供可操作的、針對患者的見解和監管級證據。

在產品層面，酵素、試劑和試劑套件等耗材決定了檢測的靈敏度和一致性，而文庫製備平台、定序儀和資料分析平台等設備則決定了通量、讀取品質和工作流程自動化。服務層面則透過生物資訊分析、計劃管理和樣品製備的專業知識進一步提升價值，減少實施阻力，加速洞察速度。產品和服務之間的這種區別影響籌資策略以及內部團隊和外部合作夥伴之間的分工。

最終用戶展現出不同的優先級，這會影響解決方案的設計和支援模型。由研究機構和大學組成的學術和政府研究機構優先考慮方法靈活性和新穎的應用；而包括醫院和獨立實驗室在內的臨床診斷實驗室則強調法規遵循、樣本可追溯性和周轉時間。受託研究機構採用交付主導的模式，需要可擴展的工作流程和強大的品管；而製藥和生物技術公司則在發現吞吐量與臨床前和臨床開發所需的嚴謹性之間取得平衡。

這種技術細分凸顯了批量測序是群體和隊列研究的支柱，長讀長測序提供了無與倫比的異構體和結構洞察，單細胞測序解決了細胞異質性問題，而空間轉錄組學則能夠捕捉組織背景。每種技術對實驗設計、數據處理和解讀都有不同的要求，成功的專案將根據特定的科學挑戰量身定做投資，同時確保在採用多種技術策略時實現互通性。

決定招募模式的區域動態和能力概況；世界主要地區的監管考量和夥伴關係機會；

地區差異導致了不同的應用模式和策略重點。在美洲，密集的研究機構和生技公司網路支撐著一個充滿活力的技術應用、轉化合作和公私合營關係生態系統。這種環境促進了新型定序方法的快速部署，並促進了設備供應商和早期採用者之間的密切合作，而法律規範和報銷途徑則持續影響臨床應用的時間表。

歐洲、中東和非洲呈現出多元化的格局，協調一致的監管環境、跨境研究聯盟和國家資金籌措計畫正在塑造能力建設。該地區許多國家正在對基礎設施進行戰略投資，以支持基因組醫學和轉化研究，為聯盟主導的研究以及區域製造和經銷夥伴創造了機會。同時，不同的管理體制鼓勵強調互通性、資料保護和跨司法管轄區合規的解決方案。

在亞太地區，對創新工作流程的規模化、在地化和快速應用的關注，正在推動學術中心和商業生物技術公司進行大量投資。該地區的優先事項通常包括建立國內生產能力、擴展臨床測序服務以及整合數位健康平台。因此，在這些地區營運的公司和機構必須根據採購慣例、監管期望以及支持大規模部署的區域夥伴關係關係的差異，量身定做其合作策略。

公司層面的競爭定位、夥伴關係和能力差異化策略考量，塑造 RNA 定序生態系統

RNA定序生態系統中的領先公司透過整合專有化學技術、儀器工程、軟體生態系統和降低進入門檻的服務，脫穎而出。將強大的硬體與可擴展的雲端分析技術以及強大的客戶支援相結合的公司，能夠為高通量研究和臨床客戶創造永續的優勢。此外，提供整合耗材和檢驗的工作流程的供應商可以減少差異性並加快獲得結果的速度。

設備供應商、試劑製造商和生物資訊公司之間的合作正在創造更多端到端解決方案，這對尋求承包服務的機構極具吸引力。與受託研究機構和學術聯盟的策略聯盟正在進一步拓展空間轉錄組學和單細胞分析等專業應用的覆蓋範圍。同時，以服務為導向的公司提供深厚的生物資訊專業知識和樣本處理能力，正在幫助缺乏內部計算資源的研究機構填補這一空白。

隨著競爭動態的演變，投資於互通性、開放 API 和社群主導的分析框架的公司更有能力獲得研究網路的長期參與。同樣重要的是，能夠透過同行評審的檢驗和符合法規的研究來檢驗其在現實世界中的效用。這些公司層面的策略將在塑造整個生態系統的採用、合作夥伴選擇和客戶維繫發揮核心作用。

為行業領導者提供實用的優先建議，以加速採用，降低風險並從 RNA 測序投資中獲取價值

領導者首先應將技術選擇與研究目標結合，並確保所選定序方法（批量定序、單細胞定序、長讀長定序或空間定序）能夠直接解決其關鍵的生物學問題。這種協調可以減少下游返工並最佳化資源配置。其次，組織機構應投資標準化樣本工作流程和品管查核點，以確保在不同機構和研究中獲得可重複的結果，從而增強對研究發現和臨床結果的信心。

為了降低供應鏈和採購風險，研究機構應與多家供應商建立合作關係，並探索能夠在貿易政策變化時提供連續性的區域採購方案。同時，建構內部生物資訊能力，並利用外部服務合作夥伴進行專業分析，可以創建一個平衡控制力和擴充性的混合模式。投資可互通的資料基礎設施和清晰的資料管治政策，可以促進多組體學整合、協作以及對當地法規和政策的遵守。

最後，產業領導者應在開發生命週期的早期階段優先進行透明的檢驗研究和監管參與。透過嚴格的外部檢驗研究證明臨床效用和穩健性，將加速相關人員的認可，並支持下游應用。遵循這些優先行動，將使企業能夠從RNA測序技術中獲得更大的價值，同時降低營運和策略風險。

透明的調查方法，解釋如何分析資料來源以及為綜合研究結果和確保可重複性而採取的檢驗步驟

該分析整合了主要專家訪談、已發表通訊協定的技術評估以及同行評審文獻的系統綜述的結果，以三角測量趨勢和實際意義。主要的定性輸入來自實驗室主任、採購主管和生物資訊專家，旨在了解操作實踐和檢驗重點。技術評估包括對工作流程要素（例如文庫製備方法、讀長影響和樣本品質閾值）進行基準測試，以明確技術是否適合用途。

分析方法強調可重複性和可追溯性。關鍵聲明已通過多個獨立資訊來源檢驗，並闡明了方法學的局限性。比較評估著重於差異化能力而非定量市場指標，並使用案例研究來說明技術選擇如何影響藥物研發和臨床工作流程的結果。在適當的情況下，從監管文件和公開指南中獲取了有關臨床實施和合規性的見解。

該調查方法旨在為讀者提供所提出的研究結果和建議的明確理由，透過強調影響 RNA 定序技術部署和採用的技術細節和實際限制來支持明智的決策。

將技術進步的營運現實與策略行動連結並指導相關人員進行實用化。

最後，RNA定序正處於技術創新與營運轉型的交會點。單細胞、長讀長和空間轉錄組學的進步拓展了可解決的生物學問題的範圍，而不斷變化的供應鏈動態和監管環境也要求新的採購和專案管理方法。那些根據科學目標做出深思熟慮的技術選擇、投資可重複的工作流程並建立靈活夥伴關係的組織，將最有可能最大限度地發揮這些進步的價值。

展望未來，最成功的計畫將整合強大的生物資訊學，優先考慮跨學科合作，並為影響臨床應用的監管和商業性限制做好準備。透過採用彈性供應策略並投資檢驗途徑，相關人員可以加速將轉錄組學見解轉化為可操作的臨床和研究成果。這一結論強調了製定策略規劃的必要性，該規劃應兼顧創新、實用性和合規性，以實現永續的影響。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 利用整合的單細胞和空間轉錄組學進行腫瘤微環境分析
  • 擴展直接RNA定序技術以準確檢測RNA修飾
  • 結合人工智慧和機器學習進行轉錄組數據解釋
  • 用於分析全長轉錄異構體的長讀定序平台的實現
  • 引入雲原生流程來加速大規模 RNA-seq 資料分析
  • 基於NGS的腫瘤RNA診斷標準化臨床試驗的開發
  • 整合RNA定序與蛋白質體學和代謝體學的多體學方法
  • 監管協調努力簡化基於RNA的伴隨診斷的核准
  • 樣品製備工作流程高通量自動化的成本最佳化策略
  • 可攜式定序設備的出現，使照護現場轉錄組分析成為可能

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 基於NGS的RNA定序市場（依應用）

  • 生物標記發現
    • 早期生物標記識別
    • 檢驗
  • 藥物研發
    • 藥物動力學研究
    • 目標識別
    • 毒理學研究
  • 基因表現
    • 批量分析
    • 單細胞分析
    • 空間剖析
  • 個人化醫療
    • 伴隨診斷
    • 治療監測

9. 以NGS為基礎的RNA定序市場（依產品）

  • 耗材
    • 酵素
    • 試劑和套件
  • 裝置
    • 數據分析平台
    • 文庫製備設備
    • 序列器
  • 服務
    • 生物資訊分析服務
    • 計劃管理服務
    • 樣品製備服務

第 10 章基於 NGS 的 RNA定序市場（按最終用戶分類）

  • 學術和政府
    • 研究機構
    • 大學
  • 臨床診斷實驗室
    • 醫院檢查室
    • 獨立研究機構
  • 合約研究組織
  • 製藥和生物技術公司
    • 生技公司
    • 製藥公司

11. 基於NGS的RNA定序市場（依技術）

  • 批量序列
  • 長讀定序
  • 單細胞定序
  • 空間轉錄組學

12. 基於NGS的RNA定序市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 基於NGS的RNA定序市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 基於NGS的RNA定序市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies Ltd.
    • BGI Genomics Co., Ltd.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • Eurofins Scientific SE
    • PerkinElmer, Inc.
Product Code: MRR-2214614769D5

The NGS-Based RNA-Sequencing Market is projected to grow by USD 10.20 billion at a CAGR of 18.21% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.67 billion
Estimated Year [2025] USD 3.17 billion
Forecast Year [2032] USD 10.20 billion
CAGR (%) 18.21%

Comprehensive introduction to NGS-based RNA sequencing innovations and their implications for translational research clinical pipelines and bioinformatics integration

Next-generation sequencing (NGS)-based RNA sequencing has progressed from an academic curiosity to a foundational platform that underpins discovery, diagnostics, and therapeutic development. The technique's capacity to quantify transcriptomes with high sensitivity and resolution now supports diverse applications ranging from biomarker identification to the interrogation of cellular heterogeneity. As laboratories adopt more sophisticated workflows and computational pipelines, RNA sequencing increasingly informs decisions across early-stage research and clinical translation.

In addition, innovations in library preparation, read-length optimization, and multi-modal integration have expanded the utility of RNA sequencing in complex biological contexts. These technical advances have been accompanied by shifts in laboratory practices, heightened expectations for reproducible analyses, and new demands for regulatory alignment. Consequently, leaders in academia, diagnostics, and industry must understand not only the technology, but also operational considerations such as sample handling, data governance, and cross-disciplinary collaboration.

This introduction frames the discussion for stakeholders who need to align scientific capabilities with strategic objectives. It highlights why RNA sequencing is now a central asset in translational pipelines, and it outlines the contours of the landscape that follow in subsequent sections.

Transformative shifts redefining RNA sequencing research, clinical translation, and bioinformatics workflows across disciplines

The landscape of RNA sequencing has been reshaped by several convergent forces that extend beyond raw throughput improvements. First, the move from bulk to single-cell and spatial transcriptomics has fundamentally changed biological interpretation by illuminating cellular heterogeneity and tissue architecture. This transition has demanded new sample preparation protocols, refined quality controls, and analytical methods capable of resolving sparse data. As a result, research teams now design experiments with cellular resolution in mind, which influences everything from reagent selection to downstream computational resources.

Second, long-read sequencing technologies have emerged as a complementary approach, enabling the detection of full-length isoforms and complex transcript structures that short reads can miss. This capability is accelerating our understanding of alternative splicing, fusion transcripts, and transcript isoform regulation, which in turn informs target validation and biomarker refinement. The adoption of long-read approaches also requires reassessment of library construction workflows and data storage approaches because of differing error profiles and data formats.

Third, integration with multi-omics and cloud-enabled bioinformatics platforms is driving collaborative, reproducible analyses across institutions. As workflows become modular and interoperable, teams can combine transcriptomic data with proteomics and epigenomics to generate higher-confidence biological hypotheses. Taken together, these shifts are not merely technical; they alter how organizations prioritize investments, structure collaborations, and translate discovery into clinical application.

Cumulative effects of proposed United States tariffs in 2025 on operational costs supply chains and strategic sourcing for RNA sequencing workflows

Policy changes that affect tariffs can ripple through the life sciences supply chain, influencing costs, supplier relationships, and procurement strategies. In contexts where reagents, instruments, and specialized consumables cross borders, higher duties increase the landed cost of goods and create incentives to revisit sourcing strategies. For many laboratories, this results in longer procurement cycles and elevated attention to inventory management, with procurement teams prioritizing longer lead times and alternative suppliers to mitigate supply interruptions.

Moreover, tariffs can accelerate localization and near-shoring efforts as institutions and vendors seek to reduce exposure to cross-border duties and currency volatility. Suppliers may respond by establishing regional manufacturing hubs or by optimizing their product portfolios to reduce the number of tariff-affected components. In parallel, service providers and contract research organizations may adapt by offering bundled, end-to-end solutions that absorb some supply chain risks on behalf of customers, thereby simplifying procurement for research and clinical laboratories.

Consequently, research groups must reassess vendor contractual terms, explore multi-sourcing, and consider the total cost of ownership when selecting instruments and consumables. In addition, strategic purchasing decisions will increasingly weigh supply continuity, regional support, and the flexibility to pivot between reagents or platforms without compromising data comparability. Ultimately, tariff-related pressures are prompting organizations to adopt more resilient supply chain strategies and a greater emphasis on partnership models that balance cost, reliability, and performance.

Key segmentation insights linking applications products end users and technologies to differentiated workflows and value creation pathways

Analyzing adoption through the lens of application reveals distinct use-cases that shape requirements and investments. Biomarker discovery, with its focus on early-stage identification and validation, demands high-throughput reproducibility and rigorous validation pipelines to support downstream clinical translation. Drug discovery and development imposes orthogonal constraints: pharmacokinetic studies emphasize quantitative precision, target identification requires broad transcriptome coverage, and toxicology studies prioritize sensitivity for rare or low-abundance transcripts. Gene expression profiling spans bulk approaches suited to population-level signals as well as single-cell and spatial profiling that reveal cellular and microenvironmental nuances. Personalized medicine requires integration across companion diagnostics and therapeutic monitoring to deliver actionable, patient-specific insights and regulatory-grade evidence.

From a product perspective, consumables such as enzymes, reagents and kits determine assay sensitivity and consistency, while instruments including library preparation platforms, sequencers and data analysis platforms define throughput, read quality, and workflow automation. Services layer adds further value through bioinformatics analysis, project management, and sample preparation expertise that reduce adoption friction and accelerate time-to-insight. These product and service distinctions influence procurement strategies and the division of labor across internal teams and external partners.

End users exhibit varied priorities that influence solution design and support models. Academic and government research entities-comprising research institutes and universities-prioritize methodological flexibility and novel applications, whereas clinical diagnostics laboratories including hospital and independent labs emphasize regulatory compliance, sample traceability, and turnaround times. Contract research organizations operate on delivery-driven models that require scalable workflows and robust quality management, and pharmaceutical and biotechnology companies balance discovery throughput with the rigor needed for preclinical and clinical development.

Technology segmentation underscores that bulk sequencing remains a workhorse for population and cohort studies, long-read sequencing provides unmatched isoform and structural insights, single-cell sequencing resolves cellular heterogeneity, and spatial transcriptomics captures tissue context. Each technology imposes different requirements for experimental design, data processing, and interpretation, and successful programs calibrate their investments to match the specific scientific question while ensuring interoperability where multi-technology strategies are employed.

Regional dynamics and capability profiles that determine adoption patterns regulatory considerations and partnership opportunities across major global regions

Regional differences drive distinct adoption patterns and strategic priorities. In the Americas, research-intensive institutions and a dense network of biotechnology companies support a vibrant ecosystem for technology adoption, translational collaborations, and private-public partnerships. This environment encourages rapid deployment of new sequencing modalities and close engagement between instrument vendors and early adopters, while regulatory frameworks and reimbursement pathways continue to influence clinical translation timelines.

Europe, the Middle East and Africa present a heterogeneous landscape in which regulatory harmonization efforts, cross-border research consortia, and national funding initiatives shape capacity building. Many countries in this region invest strategically in infrastructure to support genomic medicine and translational research, creating opportunities for consortium-driven studies and regional manufacturing or distribution partnerships. Meanwhile, disparate regulatory regimes encourage solutions that emphasize interoperability, data protection, and cross-jurisdictional compliance.

Asia-Pacific demonstrates a strong emphasis on scale, localization, and rapid uptake of innovative workflows, with significant investments in both academic centers and commercial biotech. Regional priorities often include building domestic manufacturing capability, expanding clinical sequencing services, and integrating digital health platforms. Consequently, companies and institutions operating across these regions must tailor their engagement strategies to account for differences in procurement practices, regulatory expectations, and local partnerships that support deployment at scale.

Strategic company-level insights into competitive positioning partnerships and capability differentiation shaping the RNA sequencing ecosystem

Leading organizations in the RNA sequencing ecosystem differentiate through a combination of proprietary chemistry, instrument engineering, software ecosystems, and services that lower barriers to adoption. Companies that pair robust hardware with scalable cloud-enabled analysis and strong customer support create durable advantages for high-throughput research and clinical customers. In addition, vendors that offer integrated consumables and validated workflows reduce variability and accelerate time-to-results, which is particularly valuable for clinical diagnostics and regulated studies.

Partnerships between instrument providers, reagent manufacturers, and bioinformatics firms have produced more end-to-end solutions that appeal to organizations seeking turnkey capabilities. Strategic alliances with contract research organizations and academic consortia further extend reach into specialized applications such as spatial transcriptomics and single-cell analytics. Meanwhile, service-focused firms that provide deep bioinformatics expertise and sample handling capabilities help bridge gaps for institutions that lack in-house computational resources.

As competitive dynamics evolve, companies that invest in interoperability, open APIs, and community-driven analysis frameworks are better positioned to capture long-term engagement from research networks. Equally important is the ability to demonstrate real-world utility through peer-reviewed validations and regulatory-compliant studies that verify performance in clinically relevant settings. These company-level strategies are central to shaping adoption, partner selection, and customer retention across the ecosystem.

Practical and prioritized recommendations for industry leaders to accelerate adoption reduce risk and capture value from RNA sequencing investments

Leaders should begin by aligning research objectives with technology selection, ensuring that the chosen sequencing approach-bulk, single-cell, long-read, or spatial-directly addresses the primary biological question. This alignment reduces downstream rework and optimizes resource allocation. Next, organizations should invest in standardized sample workflows and quality-control checkpoints that enable reproducible outcomes across sites and studies, thereby enhancing confidence in both discovery and clinical results.

To mitigate supply chain and procurement risks, institutions should cultivate multi-vendor relationships and explore regional sourcing options that can provide continuity under shifting trade policies. Concurrently, building internal bioinformatics capacity while leveraging external service partners for specialized analyses creates a hybrid model that balances control with scalability. Investing in interoperable data infrastructures and clear data governance policies will facilitate multi-omics integration, collaboration, and compliance with regional regulations.

Finally, industry leaders should prioritize transparent validation studies and regulatory engagement early in the development lifecycle. Demonstrating clinical utility and robustness through rigorous, externally validated studies accelerates stakeholder buy-in and supports downstream adoption. By following these prioritized actions, organizations can extract greater value from RNA sequencing technologies while reducing operational and strategic risk.

Transparent research methodology describing data sources analytical approaches and validation steps used to synthesize findings and ensure reproducibility

The analysis synthesizes insights from primary interviews with domain experts, technical evaluation of published protocols, and systemic review of peer-reviewed literature to triangulate trends and practical implications. Primary qualitative inputs were obtained from laboratory directors, procurement leads, and bioinformatics specialists to capture operational realities and validation priorities. Technical assessments included benchmarking of workflow elements such as library preparation methods, read-length implications, and sample quality thresholds to contextualize technology fit for purpose.

Analytical methods emphasize reproducibility and traceability: key assertions were validated against multiple independent sources and methodological limitations were explicitly noted. Comparative assessments focused on capability differentiation rather than quantitative market metrics, and case studies were used to illustrate how technology choices influenced outcomes across discovery and clinical workflows. Where appropriate, regulatory documents and publicly available guidance informed considerations around clinical implementation and compliance.

This methodology aims to provide readers with a transparent basis for the findings and recommendations presented, and it supports informed decision-making by highlighting both technical nuances and practical constraints that affect deployment and adoption of RNA sequencing technologies.

Concluding synthesis connecting technological advances operational realities and strategic actions to guide stakeholders toward practical implementation

In closing, RNA sequencing stands at the confluence of technological innovation and operational transformation. Advances in single-cell, long-read, and spatial transcriptomics are expanding the scope of biological questions that can be addressed, while evolving supply chain dynamics and regulatory landscapes require new approaches to procurement and program management. Organizations that thoughtfully align technology choices with scientific objectives, invest in reproducible workflows, and build flexible partnerships will be best positioned to capture the value of these advances.

Moving forward, the most successful programs will integrate robust bioinformatics, prioritize cross-disciplinary collaboration, and prepare for regulatory and commercial constraints that influence clinical translation. By adopting resilient supply strategies and investing in validation pathways, stakeholders can accelerate the translation of transcriptomic insights into actionable clinical and research outcomes. This conclusion underscores the need for strategic planning that bridges innovation, practicality, and compliance to enable sustainable impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of single-cell and spatial transcriptomics integration for tumor microenvironment profiling
  • 5.2. Expansion of direct RNA sequencing technologies for accurate detection of RNA modifications
  • 5.3. Incorporation of artificial intelligence and machine learning for transcriptomic data interpretation
  • 5.4. Implementation of long-read sequencing platforms to resolve full-length transcript isoforms
  • 5.5. Deployment of cloud-native pipelines to accelerate large-scale RNA-seq data analysis
  • 5.6. Development of standardized clinical assays for NGS-based RNA diagnostics in oncology
  • 5.7. Integration of multiomics approaches combining RNA-seq with proteomics and metabolomics
  • 5.8. Regulatory harmonization efforts to streamline approval of RNA-based companion diagnostics
  • 5.9. Cost optimization strategies through high-throughput automation of sample preparation workflows
  • 5.10. Emergence of portable sequencing devices enabling point-of-care transcriptome analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. NGS-Based RNA-Sequencing Market, by Application

  • 8.1. Biomarker Discovery
    • 8.1.1. Early-Stage Biomarker Identification
    • 8.1.2. Validation
  • 8.2. Drug Discovery & Development
    • 8.2.1. Pharmacokinetic Studies
    • 8.2.2. Target Identification
    • 8.2.3. Toxicology Studies
  • 8.3. Gene Expression Profiling
    • 8.3.1. Bulk Profiling
    • 8.3.2. Single-Cell Profiling
    • 8.3.3. Spatial Profiling
  • 8.4. Personalized Medicine
    • 8.4.1. Companion Diagnostics
    • 8.4.2. Therapeutic Monitoring

9. NGS-Based RNA-Sequencing Market, by Product

  • 9.1. Consumables
    • 9.1.1. Enzymes
    • 9.1.2. Reagents And Kits
  • 9.2. Instruments
    • 9.2.1. Data Analysis Platforms
    • 9.2.2. Library Prep Instruments
    • 9.2.3. Sequencers
  • 9.3. Services
    • 9.3.1. Bioinformatics Analysis Services
    • 9.3.2. Project Management Services
    • 9.3.3. Sample Preparation Services

10. NGS-Based RNA-Sequencing Market, by End User

  • 10.1. Academic & Government
    • 10.1.1. Research Institutes
    • 10.1.2. Universities
  • 10.2. Clinical Diagnostics Laboratories
    • 10.2.1. Hospital Laboratories
    • 10.2.2. Independent Laboratories
  • 10.3. Contract Research Organizations
  • 10.4. Pharmaceutical & Biotechnology Companies
    • 10.4.1. Biotechnology Companies
    • 10.4.2. Pharmaceutical Companies

11. NGS-Based RNA-Sequencing Market, by Technology

  • 11.1. Bulk Sequencing
  • 11.2. Long-Read Sequencing
  • 11.3. Single-Cell Sequencing
  • 11.4. Spatial Transcriptomics

12. NGS-Based RNA-Sequencing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. NGS-Based RNA-Sequencing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. NGS-Based RNA-Sequencing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Illumina, Inc.
    • 15.3.2. Thermo Fisher Scientific Inc.
    • 15.3.3. QIAGEN N.V.
    • 15.3.4. Pacific Biosciences of California, Inc.
    • 15.3.5. Oxford Nanopore Technologies Ltd.
    • 15.3.6. BGI Genomics Co., Ltd.
    • 15.3.7. F. Hoffmann-La Roche Ltd
    • 15.3.8. Agilent Technologies, Inc.
    • 15.3.9. Eurofins Scientific SE
    • 15.3.10. PerkinElmer, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NGS-BASED RNA-SEQUENCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NGS-BASED RNA-SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NGS-BASED RNA-SEQUENCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY EARLY-STAGE BIOMARKER IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY VALIDATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TOXICOLOGY STUDIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL PROFILING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY THERAPEUTIC MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DATA ANALYSIS PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LIBRARY PREP INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SEQUENCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOINFORMATICS ANALYSIS SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PROJECT MANAGEMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SAMPLE PREPARATION SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY ACADEMIC & GOVERNMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CLINICAL DIAGNOSTICS LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY HOSPITAL LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BULK SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY LONG-READ SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SINGLE-CELL SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SPATIAL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL NGS-BASED RNA-SEQUENCING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY GENE EXPRESSION PROFILING, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PERSONALIZED MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS NGS-BASED RNA-SEQUENCING MARKET SIZE, BY END USER, 2018-2024 (USD MILLI